Skip to content

Perioperative Nutritional Support in Esophageal Cancer Patients

Perioperative Nutritional Support in Esophageal Cancer Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04190121
Acronym
NEEC
Enrollment
110
Registered
2019-12-09
Start date
2019-03-26
Completion date
2022-02-14
Last updated
2019-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Nutritional Deficiency

Keywords

esophageal cancer,nutritional support

Brief summary

Upper GI malignancies often lead to involuntary weight loss and nutritional deficits. Nutritional support, both pre- and postoperatively, may improve post-operative course and reduce length of hospital stay. This prospective randomized trial aims to investigate the above mentioned hypothesis and clarify any variants that may differ between the investigation and control group at a statistically significant level.

Detailed description

This prospective randomized trial is conducted in the 1st Propaedeutic Department of Surgery of National and Kapodistrian University of Athens. The study population consists of adults suffering from upper GI malignancy. Informed consent is obtained in written. Following this, the patient is classified in either the intervention group or the control group. Patients belonging in the control group will receive the usual postoperative care, while the patients in the intervention group will receive nutritional support perioperatively. The aforementioned usual postoperative care consists of administration of intravenous fluids until resuming oral feeding, jejunostomy feeding starting from the first postoperative day, epidural analgesics for the first four postoperative days, perioperative administration of a second generation cephalosporin plus metronidazole and thromboprophylaxis with (low moleculr weight heparin (LMWH). The patients are also receiving appropriate for any concomitant health problems (e.g. existing diabetes mellitus) and transfusions based on their needs. We record the patient's age, the stage and histologic type of the disease, administration of adjuvant and/or neoadjuvant therapy and the patient's American Society of Anesthesiologists Score. Their preoperative nutritional state will be assessed using Body Mass Index (BMI), serum albumin, body fat percentage, muscle mass and total body water following measurement with body composition analyzer (Tanita MC-780U Multi Frequency Segmental Body Composition Analyzer). At their initial assessment the patients will fill in an appropriate quality of life questionnaire. The type of the operation, the use of drains and catheters, the patients needs in iv fluids, blood product transfusions, sedatives and analgesics during the operation will also be recorded. The postoperative course of any patient will be closely monitored, including the postoperative needs in fluid administration and analgesics, the need for transfusion, the administration of perioperative antibiotics, the removal of drains and catheters, the time of first bowel movement,the need of ICU hospitalization, the total length of hospital stay as well as any in-hospital complications. Upon discharge from the hospital, the control group will receive instructions on oral and jejunostomy feeding, while the intervention group will receive additional nutritional support for 3 months. Both patient groups will undergo post-operative follow-up for six months. In the first, third and sixth postoperative month body weight and its change, BMI, serum albumin, body fat percentage, muscle mass and total body water, as well as quality of life, postoperative complications and need for readmission will be evaluated. Neoadjuvant therapy will also be taken into account. The results will be statistically evaluated after appropriate stratification.

Interventions

DIETARY_SUPPLEMENTprosure

The study group will receive the dietary supplement preoperatively and for three months after the operation

Sponsors

THEODOROU DIMITRIOS
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with esophageal cancer * 18 years or older

Exclusion criteria

-none

Design outcomes

Primary

MeasureTime frameDescription
infective complicationsfirst six postoperative monthssurgical site infection,pneumonia,intraabdominal sepsis,postoperative fever or other signs of sepsis

Secondary

MeasureTime frameDescription
postoperative arrhythmia or other cardiac complicationsfirst six postoperative monthscardiac complications confirmed by ECG that required consultation by a cardiologist
readmission ratefirst six postoperative months
length of stay in the ICUfirst six postoperative months
disease-associated death during the first six postoperative monthsfirst six postoperative monthsdeath related to the known malignancy,including postoperative complications
length of hospital stayfirst six postoperative months (including first admission and any other readmission)postoperative duration of hospital stay
reoperationfirst six postoperative monthsneed for reoperation due to postoperative complications in the first six postoperative months
anastomotic leakfirst six postoperative monthsanastomotic leak confirmed either by a CT scan or upper gastrointestinal series

Other

MeasureTime frame
patient's body fat changesfirst six postoperative months
patient's serum albumin changesfirst six postoperative months
patient's BMI changesfirst six postoperative months
patient's muscle mass changesfirst six postoperative months

Countries

Greece

Contacts

Primary ContactAthina-Despina Kimpizi
despinakimpizi@yahoo.com00302132088142

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026